The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Open accessAbstract
BACKGROUND: Pemphigus vulgaris is a potentially fatal autoimmune mucocutaneous blistering disease. Conventional therapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune globulin. METHODS: We studied patients with refractory pemphigus vulgaris involving 30% or more of their body-surface area, three or more mucosal sites, or both who had inadequate responses to conventional therapy and intravenous immune globulin. We treated the patients with two cycles of rituximab (375 mg per square meter of body-surface area) once weekly for 3 weeks and intravenous immune globulin (2 g per kilogram of body weight) in the fourth week. This induction therapy was followed by a monthly infusion of rituximab and intravenous immune globulin for 4 consecutive months. Titers of serum antibodies against keratinocytes and numbers of peripheral-blood B cells were monitored. RESULTS: Of 11 patients, 9 had rapid resolution of lesions and a clinical remission lasting 22 to 37 months (mean, 31.1). All immunosuppressive therapy, including prednisone, could be discontinued before ending rituximab treatment in all patients. Two patients were treated with rituximab only during recurrences and had sustained remissions. Titers of IgG4 antikeratinocyte antibodies correlated with disease activity. Peripheral-blood B cells became undetectable shortly after initiating rituximab therapy but subsequently returned to normal values. Side effects that have been associated with rituximab were not observed, nor were infections. CONCLUSIONS: The combination of rituximab and intravenous immune globulin is effective in patients with refractory pemphigus vulgaris.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Mizoguchi, A., & Bhan, A. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.705 · Cited by 582
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Keogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Rituximab in the treatment of dermatomyositis: An open‐label pilot study
Levine, T. D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20849 · Cited by 440
Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases
Rastetter, W., Molina, A., & White, C. A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104249 · Cited by 213
Bhol, K., Natarajan, K., Nagarwalla, N., Mohimen, A., Aoki, V, & Ahmed, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5239 · Cited by 200
Self-citationAnti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
Arin, M. J., Engert, A., Krieg, T. M., & Hunzelmann, N. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06651.x · Cited by 144
Sokos, D. R., Berger, M., & Lazarus, H. M. (2002) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.2002.v8.pm11939601 · Cited by 100
Correlation of Subclasses of IgG with Disease Activity in Pemphigus vulgaris
Bhol, K. C., Mohimen, A., & Ahmed, R. (2009) · Dermatology · doi:10.1159/000246938 · Cited by 88
Schmidt, E., Herzog, S., Brocker, E.-B., Zillikens, D., & Goebeler, M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06740.x · Cited by 79
Cited by
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30070-3 · Cited by 623
Schmidt, E., Kasperkiewicz, M., & Joly, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31778-7 · Cited by 559
Kasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S., & Amagai, M. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.26 · Cited by 523
Metadata
- Authors
- Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-26
- Volume
- 355
- Issue
- 17
- Pages
- 1772-1779
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2088574571
- Cited by
- 456
- References
- 12
- FWCI
- 24.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.